2025³â 04¿ù 17ÀÏ ¸ñ¿äÀÏ
 
 
  ÇöÀçÀ§Ä¡ > ´º½ºÁö´åÄÄ > Business

·£¼¶¿þ¾îºÎÅÍ µÅÁöµµ»ì±îÁö... ³ë·ÃÇØÁø »ç±âÇà°¢

 

Á¤Ä¡

 

°æÁ¦

 

»çȸ

 

»ýȰ

 

¹®È­

 

±¹Á¦

 

°úÇбâ¼ú

 

¿¬¿¹

 

½ºÆ÷Ã÷

 

ÀÚµ¿Â÷

 

ºÎµ¿»ê

 

°æ¿µ

 

¿µ¾÷

 

¹Ìµð¾î

 

½Å»óǰ

 

±³À°

 

ÇÐȸ

 

½Å°£

 

°øÁö»çÇ×

 

Ä®·³

 

Ä·ÆäÀÎ
Çѻ츲 ¡®¿ì¸®´Â ÇѽҸ²¡¯ ½Ò ¼Òºñ Ä·ÆäÀÎ ½Ã...
1000¸¸¿øÂ¥¸® Àΰø¿Í¿ì, °Ç°­º¸Çè Áö¿ø ¡®Æò...
- - - - - - -
 

Galderma Launches Restylane VOLYME in China - One of the World¡¯s Fastest Growing Aesthetics Markets

Restylane VOLYME is designed for contouring and volumization of the mid-face region to support patients in achieving a youthful, revitalized look
´º½ºÀÏÀÚ: 2024-05-29

ZUG, SWITZERLAND -- Galderma (SWX:GALD) announced today the launch of its hyaluronic acid injectable filler, Restylane VOLYME in China. The company is also introducing its complementary Shape Up Holistic Individualized Treatment (HIT) in the country, which addresses aging concerns caused by loss of structural support in the mid-face. The availability of these targeted solutions for the mid-face region is demonstrative of Galderma’s commitment to meeting patient and injector needs in China. In the past decade, the growth of China’s aesthetics medicine market has outpaced the global market; with relatively low market penetration, there remains significant potential for future growth.[1]

Developed using Galderma’s proprietary OBT* gel technology, Restylane VOLYME is indicated for the correction of mid-face volume deficit and/or mid-face contour deficiency through injections into the subcutaneous to supraperiosteal layers of the skin.[2-3] Hyaluronic acid fillers are often patients’ first choice for mid-face augmentation and have been shown to deliver high patient satisfaction and long-lasting effects.[4] In China, hyaluronic acid fillers are among the top 10 most-sold aesthetics products.[1]

“We are delighted to deliver Galderma’s innovative aesthetics solutions in China with the support of our research and development teams, as well as local partners and regulatory authorities. As the Chinese market continues to expand, we look forward to working closely with all stakeholders to deliver our full, premium range of aesthetics products to meet the varied and individual needs of patients and injectors.”
GERRY MUHLE HEAD OF GLOBAL PRODUCT STRATEGY GALDERMA

Developed with a global community of injectors, the Shape Up HIT is the latest of Galderma’s HITs to be introduced in China, designed to create a common language to facilitate a two-way dialogue between patient and practitioner to align on patient priorities and keep satisfaction at the forefront.

“Aesthetic plastic surgery is an artistic creation under medical constraints, embodying a holistic and individualized approach. Facial expressions are controlled by 42 muscles which convey emotions such as joy, anger, sorrow, and happiness. These muscles are also involved in language, chewing, and other activities. The appearance of the mid-face is crucial in interpersonal communication. Together, Restylane VOLYME and the Shape Up HIT enable patients to maintain their natural facial expressions while also supporting injectors to deliver a youthful and long-lasting aesthetic effect.”
PROFESSOR HAIYAN CUI DIRECTOR OF THE INSTITUTE OF AESTHETIC PLASTIC SURGERY AND MEDICINE TONGJI UNIVERSITY DIRECTOR OF THE PLASTIC & COSMETIC SURGERY DEPARTMENT TONGJI HOSPITAL OF TONGJI UNIVERSITY

HIT is an individualized treatment approach which enables injectors to leverage their expertise with the renowned Galderma Restylane portfolio to optimize aesthetic outcomes while prioritizing patient satisfaction. The Balanced Profile HIT was Galderma’s first HIT to be introduced in China in 2023, providing a framework for practitioners to conduct a full objective facial assessment for the patient and help bring balance to their profile. HIT naturally springboards from Galderma’s AART (Assessment, Anatomy, Range, Treatment) methodology for a new generation of individualized aesthetics.

Restylane is the largest and most diverse range of individually engineered hyaluronic acid fillers on the market, approved in more than 80 countries and regions, and with over 65 million treatments administered worldwide.[5-8]



 Àüü´º½º¸ñ·ÏÀ¸·Î

Giesecke+Devrient Continues Strong Growth Trajectory
Western Union Offers Zero-Fee International Money Transfers to Myanmar
Barilla Ranks as the First Food Company in the World for Reputation in the 2025 Global RepTrak¢ç 100
PUMA to Open First-Ever European Flagship Store on Oxford Street in Autumn 2025
Lone Star Funds Announces Sale of Japanese Rental Property Portfolio Tokyo ¥â
Former Mitsubishi IP Leader to Head Sisvel Japan
Guidewire Mammoth Release Builds on Momentum of Advancing Insurance Operations

 

Bringg Welcomes Yishay Schwerd as Chief Product and Technology Officer
Interactive Brokers Adds Multi-Monitor Support and More to IBKR Deskto...
Esri Releases Expanded Edition of the World¡¯s Most Comprehensive GIS ...
Parse Biosciences Partners with Japanese Distributor, SCRUM Inc.
SINOVAC Announces Decision to Declare Cash Dividend
Everen Group Promotes Karyn Peixoto to Chief HR Officer
NIQ's Global Report Reveals Challenges and Opportunities for Private L...

 


°øÁö»çÇ×
¹Ìµð¾î¾Æ¿ì¾î Mediaour ØÚ体ä²们 ØÚô÷ä²Ùú MO ¿¥¿À ØÚä² ØÚä²
¾Ë¸®¿ìºê Alliuv ä¹备: ä¹联êó备, ¾Ë¶ã Althle ä¹÷åìÌ
¾Ë¸®¾Ë Allial Áß¹® Ç¥±â ä¹××尔 ä¹××ì³
´ºÆÛ½ºÆ® New1st Áß¹® Ç¥±â 纽ììãæ(¹øÃ¼ Òïììãæ), N1 纽1
¿£ÄÚ½º¸ð½º : À̾¾ 'EnCosmos : EC' Áß¹® Ç¥±â ì¤ñµ
¾ÆÀ̵ð¾î·Ð Idearon Áß¹® Ç¥±â ì¤îè论 ì¤îèÖå
¹ÙÀÌ¿ÀÀÌ´Ï Bioini Áß¹® Ç¥±â ù±药研 ù±å·æÚ
¿À½ºÇÁ·Ò Ausfrom 奥ÞÙÜØÙÌ, À£ÇÁ·Ò Welfrom 卫ÜØÙÌ
¿¡³ÊÇÁ·Ò Enerfrom 额ÒöÜØÙÌ ¿¡³ÊÀ¯ºñ Eneruv 额Òöêó备
º£³×ÇÁ·Ò º£³×ÀÎÅõ Áß¹® Ç¥±â 宝Ò¬ÜØÙÌ 宝Ò¬ì×öõ(ÜÄÒ¬ÜØÙÌ ÜÄ...
¾ËÇÁ·Ò Alfrom Áß¹® Ç¥±â ä¹尔ÜØÙÌ ä¹ì³ÜØÙÌ
´º½ºÁö ÇÑÀÚ Ç¥±â¿¡ ´ë¸¸½Ä À½Â÷ Ç¥±â '纽ÞÙó¢ ´Ï¿ì½ÃÁö' º´±â

 

ȸ»ç¼Ò°³ | ÀÎÀçä¿ë | ÀÌ¿ë¾à°ü | °³ÀÎÁ¤º¸Ãë±Þ¹æÄ§ | û¼Ò³âº¸È£Á¤Ã¥ | Ã¥ÀÓÇѰè¿Í ¹ýÀû°íÁö | À̸ÞÀÏÁÖ¼Ò¹«´Ü¼öÁý°ÅºÎ | °í°´¼¾ÅÍ

±â»çÁ¦º¸ À̸ÞÀÏ news@newsji.com, ÀüÈ­ 050 2222 0002, ÆÑ½º 050 2222 0111, ÁÖ¼Ò : ¼­¿ï ±¸·Î±¸ °¡¸¶»ê·Î 27±æ 60 1-37È£

ÀÎÅͳݴº½º¼­ºñ½º»ç¾÷µî·Ï : ¼­¿ï ÀÚ00447, µî·ÏÀÏÀÚ : 2013.12.23., ´º½º¹è¿­ ¹× û¼Ò³âº¸È£ÀÇ Ã¥ÀÓ : ´ëÇ¥ CEO

Copyright ¨Ï All rights reserved..